OTCMBSEM
Market cap229mUSD
Jan 23, Last price
13.11USD
1D
-10.62%
1Q
0.50%
Jan 2017
39.80%
Name
Biostem Technologies Inc
Chart & Performance
P/E
—
P/S
12.83
EPS
—
Div Yield, %
—
Shrs. gr., 5y
11.08%
Rev. gr., 5y
74.98%
Revenues
17m
+142.69%
Net income
-8m
L+19.90%
CFO
-3m
L+113.75%
Earnings
Mar 31, 2025
Profile
BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr. Dave's Best and Nesvik Organics brands, as well as other non-proprietary products in the United States and internationally. The company sells products through e-commerce platforms. BioStem Technologies, Inc. was incorporated in 2006 and is based in Pompano Beach, Florida.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 16,685 142.69% | 6,875 58.38% | |||||||
Cost of revenue | 23,515 | 11,530 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (6,829) | (4,655) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 430 | ||||||||
Tax Rate | |||||||||
NOPAT | (6,829) | (5,085) | |||||||
Net income | (8,483) 19.90% | (7,075) 389.48% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 2,380 | 50 | |||||||
BB yield | -2.96% | -0.15% | |||||||
| Debt | |||||||||
Debt current | 4,490 | 4,051 | |||||||
Long-term debt | 347 | 1,058 | |||||||
Deferred revenue | (111) | ||||||||
Other long-term liabilities | 51 | ||||||||
Net debt | 4,598 | 4,337 | |||||||
| Cash flow | |||||||||
Cash from operating activities | (3,499) | (1,637) | |||||||
CAPEX | (105) | (469) | |||||||
Cash from investing activities | (210) | (469) | |||||||
Cash from financing activities | 3,177 | 573 | |||||||
FCF | (8,845) | (6,965) | |||||||
| Balance | |||||||||
Cash | 239 | 772 | |||||||
Long term investments | |||||||||
Excess cash | 428 | ||||||||
Stockholders' equity | (45,608) | (36,884) | |||||||
Invested Capital | 49,038 | 37,963 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 13,707 | 11,405 | |||||||
Price | 5.86 95.99% | 2.99 187.50% | |||||||
Market cap | 80,323 135.54% | 34,102 180.61% | |||||||
EV | 84,921 | 38,566 | |||||||
EBITDA | (6,434) | (4,411) | |||||||
EV/EBITDA | |||||||||
Interest | 468 | ||||||||
Interest/NOPBT | |||||||||